Blocking the voltage‐gated sodium channel hNa v 1 .5 as a novel pH ‐dependent mechanism of action for tamoxifen
FEBS Open Bio · 2025
DOI: 10.1002/2211-5463.70091 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, 2025. Verfasst von Karl Josef Föhr und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Intensive Care Medicine, University Hospital Ulm, Germany. Hauptthemen laut MEDLINE: Tamoxifen, NAV1.5 Voltage-Gated Sodium Channel, Voltage-Gated Sodium Channel Blockers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tamoxifen, a selective estrogen receptor modulator, is widely used in breast cancer treatment, but also affects estrogen receptor‐negative tumors, suggesting alternative mechanisms. Voltage‐gated sodium channels (VGSCs) are implicated in metastasis, making them potential therapeutic targets. However, broad VGSC inhibition is impractical due to their essential physiological roles. Ideally, blockers should selectively target tumor‐associated VGSC properties while sparing normal cells. Since tamoxifen exhibits sodium channel‐blocking activity, we investigated its effects on tumor‐specific VGSC parameters. Electrophysiological experiments using the patch‐clamp technique were conducted on heterologously expressed human cardiac sodium channels (hNa v 1.5). Tamoxifen does not differentiate between the adult and embryonic splice variants of hNa v 1.5, the latter being predominant in tumors. However, it effectively blocks hNa v 1.5 in gating states (slow‐inactivated and open) assumed to be prevalent in cancer cells. Binding affinity increases significantly under acidic conditions (pH 6.0 vs. 7.4), mimicking the tumor microenvironment. The affinity for the slow‐inactivated state was 0.87 ± 0.16 μ m at pH 7.4 and 0.16 ± 0.02 μ m at pH 6.0. For the open state, half‐maximal inhibition occurred at 2.13 ± 0.08 μ m and 0.57 ± 0.02 μ m , respectively. Tamoxifen preferentially binds VGSCs under conditions characteristic of cancer tissue, particularly at acidic pH, suggesting its potential as a selective tumor‐targeting agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Intensive Care Medicine, University Hospital Ulm, Germany.
- Institute of Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Germany.
- Institute of General Physiology, University of Ulm, Germany.
- Institute of Physiology, University Hospital of Jena, Germany.
- Institute of Transfusion Medicine, University Hospital Ulm, Germany.
ORCID-Profile: David Alexander Christian Messerer
Zitieren
APA
Föhr, K. J., Fauler, M., Zimmer, T., Jungwirth, B., Schrezenmeier, H., & Messerer, D. A. C. (2025). Blocking the voltage‐gated sodium channel hNa v 1 .5 as a novel pH ‐dependent mechanism of action for tamoxifen. FEBS Open Bio. https://doi.org/10.1002/2211-5463.70091
Vancouver
Föhr KJ, Fauler M, Zimmer T, Jungwirth B, Schrezenmeier H, Messerer DAC. Blocking the voltage‐gated sodium channel hNa v 1 .5 as a novel pH ‐dependent mechanism of action for tamoxifen. FEBS Open Bio. 2025. doi:10.1002/2211-5463.70091
BibTeX
@article{Fhr2025,
author = {Föhr, Karl Josef and Fauler, Michael and Zimmer, Thomas and Jungwirth, Bettina and Schrezenmeier, Hubert and Messerer, David Alexander Christian},
title = {Blocking the voltage‐gated sodium channel hNa v 1 .5 as a novel pH ‐dependent mechanism of action for tamoxifen},
journal = {FEBS Open Bio},
year = {2025},
doi = {10.1002/2211-5463.70091}
}
EUVIMED